Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer’s disease
Our novel assays demonstrated good analytical and clinical performance. CSF β-syn reliably indicates early synaptic degeneration in AD. The mid-region assay uniquely differentiated SCD-AD from AD-dem, showing promise for early disease detection.
Authors
- Sherif Bayoumy (ORCID: https://orcid.org/0000-0002-3480-5136)
- Nicholas C. Barrett
- Wiesje M. van der Flier (ORCID: https://orcid.org/0000-0001-8766-6224)
- Julie Goossens (ORCID: https://orcid.org/0000-0001-5336-1238)
- Inge M.W. Verberk (ORCID: https://orcid.org/0000-0003-0341-7445)
- Charlotte Elisabeth Teunissen (ORCID: https://orcid.org/0000-0002-4061-0837)
- Eugeen Vanmechelen (ORCID: https://orcid.org/0000-0002-9466-5366)
- Charlotte De Rocker
- Senna Y Sie
Institutions
- Ablynx (Belgium) (BE)
- Amsterdam Neuroscience (NL)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1186/s13195-025-01716-8
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Noaber Foundation
- Amsterdam University Medical Centers
- Stichting Dioraphte